综述:非酒精性脂肪性肝病与代谢综合征之间的共享疾病机制——将系统生物学知识转化为临床实践
本综述采用系统生物学策略,通过基因/蛋白-疾病相互作用网络、基因-疾病富集分析和基因-药物连接网络,探讨非酒精性脂肪性肝病(NAFLD)与代谢综合征的共享疾病机制。研究发现共享基因/蛋白网络富集于免疫应答通路、核受体翻译后修饰和血小板相关过程,并提示NAFLD治疗需采用多靶点策略。
要点
- NAFLD与代谢综合征存在共享的基因/蛋白相互作用网络,富集于免疫应答、核受体翻译后修饰和血小板相关过程。
- 基因-疾病富集分析提示共享分子效应器涉及自身免疫病、肾脏、呼吸、神经系统疾病、癌症和感染性疾病。
- 作者认为NAFLD治疗(包括严重组织学特征)不能限于单一药物,而需多靶点治疗策略。
核心结论
- 作者提供证据表明,NAFLD治疗(包括严重组织学特征)不能限于使用单一药物,而需要多靶点治疗策略。
研究设计与样本
- 本综述采用系统生物学策略,通过映射共享基因/蛋白-疾病相互作用网络、进行基因-疾病富集分析以评估多效性,并构建基因-药物连接网络。
主要发现
- 共享基因/蛋白网络过度代表免疫应答相关通路、核受体翻译后修饰和血小板相关过程(包括激活和血小板信号传导)。
- 基因-疾病富集分析提示共享分子效应器涉及多种自身免疫病、肾脏、呼吸和神经系统疾病、癌症和感染性疾病。
- 共享基因/蛋白列表富集于抗炎治疗药物靶点、心血管疾病治疗药物、抗菌药物和植物化学物等多种已批准药物化合物的靶点。
- 利用公开可用的组学数据表明,共享位点不一定受反向因果关系影响。
临床怎么用
- 作者认为NAFLD治疗(包括严重组织学特征)不能限于单一药物,而需要多靶点治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide. Characterised by abnormal fat accumulation in the liver, NAFLD presents high degree of comorbidity with disorders of the metabolic syndrome, including type 2 diabetes, obesity and cardiovascular disease. These comorbidities have strong negative impact on the natural course of NAFLD and vice versa, whereby the presence of NAFLD substantially modifies the course and prognosis of metabolic syndrome-associated diseases. AIM: To use systems biology strategies to interrogate disease mechanisms that are common to NAFLD and metabolic syndrome. METHODS: We mapped shared gene/protein-disease interaction networks, we performed gene-disease enrichment analysis to assess pleiotropy, and we created a gene-drug connectivity network. RESULTS: We found that a shared network of genes/proteins is overrepresented by immune response-related pathways, post-translational modifications of nuclear receptors, and platelet-related processes, including activation and platelet signalling. Likewise, gene-based disease-enrichment analysis suggested underlying molecular effectors that are shared with major systemic disorders, including diverse autoimmune diseases, kidney, respiratory and nervous system disorders, cancer and infectious diseases. The shared list of genes/proteins was enriched in drug targets for anti-inflammatory therapy, drugs used to treat cardiovascular diseases, antimicrobial agents and phytochemicals, among many other approved pharmaceutical compounds. By leveraging on publicly available OMICs data, we were able to show that shared loci are not necessarily affected by reverse causality. CONCLUSION: We provide evidence indicating that NAFLD treatment, including severe histological traits, cannot be limited to the use of a single drug, as it rather requires a multi-target therapeutic approach.
引用
- Sookoian S, Pirola CJ. Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside. Aliment Pharmacol Ther. 2019. PMID: 30714632. doi:10.1111/apt.15163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。